Perimenopause and Sleep: Night Sweats, 3am Waking, and What Helps

TL;DR30-second take

Sleep disturbance affects roughly 40 to 60 percent of women during the menopause transition, driven by vasomotor symptoms causing night-time arousals, falling progesterone whose metabolites are sedating, mood changes, and a substantial rise in obstructive sleep apnea risk after menopause. Treatments that address the cause include hormone therapy where appropriate, micronized progesterone taken at bedtime, and non-hormonal options for vasomotor symptoms. CBT-I has evidence specifically in menopausal insomnia. Because apnea risk rises at this same stage, screening for it should precede any sedating prescription.

TL;DR: Sleep falls apart for a lot of women in the menopause transition, and there are four separate reasons, which is why one fix rarely covers it. Hot flashes and night sweats wake you. Progesterone falls, and progesterone breaks down into something sedating, so losing it costs you sleep directly. Mood changes make it worse. And sleep apnea risk rises sharply after menopause, which almost nobody mentions. That last one matters most, because the standard response is a sleeping pill, and sedating an undiagnosed apnea is the wrong direction. Treatments that work on the cause include hormone therapy where it fits, progesterone taken at bedtime, non-hormonal options for the flashes, and CBT-I, which has evidence in this very group. Get the thyroid checked too. Tell Dr. Ash what your nights look like.

A very common story: a woman in her late forties, sleeping well her whole life, now waking at three most nights, soaked, and unable to get back down. She has been offered a sleeping pill and an antidepressant and has not been asked a single question about her cycle.

There are four mechanisms here, they overlap, and the treatment depends on which ones are running.

Why does sleep fall apart in perimenopause?

Vasomotor symptoms, meaning hot flashes and night sweats. A flash produces a surge of heat, sweating, and often a burst of adrenaline, and it arrives with an arousal from sleep. Women often report the waking before they notice the sweat, because the arousal comes first. Repeated through the night, this fragments sleep even when total time in bed is unchanged.

Falling progesterone. Progesterone is metabolized to allopregnanolone, which acts on GABA-A receptors and is sedating and anxiolytic. As progesterone declines, that endogenous sedative goes with it. This is a direct pharmacological loss and it explains why some women describe sleep changing before any flash ever appeared.

Mood. Depression and anxiety both rise during the transition, and both disturb sleep independently. Early-morning waking deserves a look at mood before it is attributed to hormones by default.

Rising sleep apnea risk, which is the one that gets missed, and it has its own section below.

Two more to keep on the list: restless legs, which worsens with the iron deficiency common in the years of heavy bleeding that often precede menopause, and thyroid disease, which produces night sweats, palpitations, and insomnia and mimics the whole picture closely.

Why does sleep apnea risk rise after menopause?

Because progesterone and estrogen are protective, and losing them removes the protection.

Progesterone is a respiratory stimulant and both hormones support upper airway muscle tone, so the premenopausal hormonal environment is partly why obstructive sleep apnea is less common in younger women than in men of the same age. That gap narrows substantially after menopause, and postmenopausal women carry a markedly higher risk than premenopausal women of the same weight.

The problem is what it looks like. Apnea in women presents more often as insomnia, fatigue, and low mood than as loud snoring and daytime sleepiness, which is the same picture already being attributed to the menopause transition. The result is a woman with a treatable airway problem being managed for menopausal insomnia for years.

The practical instruction: if you are waking unrefreshed after adequate hours, waking with a gasp, getting up repeatedly to urinate, waking with headaches, or your blood pressure has stopped responding to medication, get tested. The distinguishing features are on insomnia or sleep apnea and the testing options are on home sleep apnea testing.

Guidance from the Clinic

"A woman comes in on a sleeping pill and an antidepressant, both started for menopausal insomnia, neither working well. Nobody has checked her thyroid and nobody has asked whether her husband has seen her stop breathing. Those are two questions and one blood test, and they change the answer often enough that skipping them is not defensible."

What treatments address the cause?

Hormone therapy, where it fits. Estrogen is the most effective treatment for vasomotor symptoms, and reducing the flashes reduces the arousals that fragment sleep. Whether it fits depends on time since menopause, cardiovascular and breast cancer risk, and what matters to the individual, which is a proper conversation and not a web form. The evidence and how it is weighed here is on perimenopause and bioidentical hormone safety.

Micronized progesterone at bedtime. For women with a uterus taking estrogen, progesterone is required to protect the endometrium, and the timing is a free win, because a metabolite that sedates does more good at night than during the day. Some women report the sleep benefit as the most noticeable effect of their whole regimen.

Non-hormonal options for vasomotor symptoms, for women who cannot or prefer not to take hormones. Low-dose paroxetine holds FDA approval for hot flashes, other SSRIs and SNRIs are used, gabapentin reduces night-time flashes and has its own sedating effect, and fezolinetant, a neurokinin-3 receptor antagonist approved in 2023, works on the brain pathway driving flashes without hormones. Gabapentin here carries the cautions on its own page.

CBT-I, which has been tested specifically in menopausal women with insomnia and improves both sleep and, in some trials, the bother of the hot flashes themselves. It is first-line for chronic insomnia in every guideline and it does not interact with anything. CBT-I for insomnia covers what it involves.

What about the practical measures?

They matter more here than in most insomnia, because the trigger is thermal.

Keep the bedroom properly cool, in the low to mid sixties Fahrenheit. Use layers you can throw off without waking your partner, and moisture-wicking sleepwear and bedding, which sound like marketing and make a measurable difference to how long you are awake after a sweat. A cooling mattress topper or a fan aimed across the bed helps.

Alcohol, spicy food, and caffeine are common flash triggers and are worth testing individually over a couple of weeks instead of eliminating all at once. Alcohol earns its own mention: it also fragments the second half of the night independently and worsens apnea.

Regular exercise improves sleep and vasomotor symptoms both, and heavy exercise in the three hours before bed works against you.

What should be checked before any of this?

Thyroid function, because hyperthyroidism produces night sweats, palpitations, anxiety, and insomnia, and is easy to attribute to menopause.

Ferritin, because restless legs is common, worsens with low iron stores, and the years before menopause are often years of heavy bleeding.

A sleep apnea screen, for the reasons above.

A mood assessment, because depression and anxiety are both more prevalent during the transition and both need naming instead of being folded into a hormone conversation.

A medication review, since a number of common drugs cause or worsen night sweats.

At Fishtown Medicine this runs inside membership, because the transition takes years and the adjustments are made over that time. How that works is on perimenopause care.

Key Takeaways

Four mechanisms run at once: vasomotor arousals, falling progesterone, mood, and rising sleep apnea risk.
Progesterone's metabolite is sedating, so losing it costs sleep directly and bedtime dosing recovers some of it.
Sleep apnea risk climbs sharply after menopause and presents as insomnia, which is why it gets missed.
Screen for apnea, check thyroid and ferritin, and assess mood before anybody prescribes a sedative.
CBT-I has been tested in menopausal women specifically and works alongside treatment for the flashes.

Scientific References

Baker FC, de Zambotti M, Colrain IM, Bei B. Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nature and Science of Sleep. 2018;10:73-95.
Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. American Journal of Respiratory and Critical Care Medicine. 2001;163(3):608-613.
Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2003;167(9):1181-1185.
Schüssler P, Kluge M, Yassouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology. 2008;33(8):1124-1131.
McCurry SM, Guthrie KA, Morin CM, et al. Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms. JAMA Internal Medicine. 2016;176(7):913-920.
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1). The Lancet. 2023;401(10382):1091-1102.
The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.

Fishtown Medicine | Hormones

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Waking in the early hours during the menopause transition is most often driven by a vasomotor event, since a hot flash arrives with an arousal from sleep and the waking is often noticed before the heat. Falling progesterone contributes independently, because its metabolite allopregnanolone is sedating and declines with it. Persistent early-morning waking should also prompt assessment for depression and for obstructive sleep apnea, whose risk rises substantially after menopause.

Micronized progesterone is metabolized to allopregnanolone, which acts on GABA-A receptors and produces sedation, so taking it at bedtime instead of in the morning puts that effect to use. Women with a uterus taking estrogen therapy require progesterone for endometrial protection regardless, which makes the timing a free gain. Many women report the sleep improvement as the most noticeable effect of their regimen.

Yes, substantially. Progesterone acts as a respiratory stimulant and both progesterone and estrogen support upper airway muscle tone, so their decline removes protection that made obstructive sleep apnea less common in premenopausal women. Postmenopausal women carry markedly higher risk than premenopausal women of similar weight, and because apnea in women often presents as insomnia and fatigue instead of snoring, it is frequently attributed to menopause and missed.

Non-hormonal options with evidence include low-dose paroxetine, which holds FDA approval for vasomotor symptoms, other SSRIs and SNRIs, gabapentin, which reduces night-time flashes and is itself sedating, and fezolinetant, a neurokinin-3 receptor antagonist approved in 2023 that acts on the hypothalamic pathway generating flashes. Environmental measures including a cool bedroom, layered bedding, and moisture-wicking sleepwear reduce how long a woman stays awake after an event.

Sedating medication treats the symptom while leaving the cause running, and in this group the cause is frequently something that responds to a different treatment: vasomotor symptoms, low progesterone, mood, thyroid disease, or obstructive sleep apnea. Because apnea risk rises sharply after menopause and often presents as insomnia, screening for it should precede any sedating prescription. CBT-I has been tested specifically in menopausal women and is first-line for chronic insomnia.

Deep-Dive Questions

Progesterone is converted to allopregnanolone, a neurosteroid that acts as a positive allosteric modulator at GABA-A receptors, producing sedative and anxiolytic effects through the same receptor family that benzodiazepines act on. Declining progesterone therefore removes an endogenous sedative, which is a pharmacological loss independent of any vasomotor symptom. This explains the common report of sleep changing before hot flashes ever appear, and why bedtime dosing of micronized progesterone is often noticed as a sleep effect.

Two mechanisms compound. Women present more often with insomnia, fatigue, morning headache, and low mood than with loud snoring and witnessed apnea, so the clinical picture matches the physician's template for menopausal insomnia or depression. Events in women are also more likely to be hypopneas and to cluster in REM sleep, which can produce a lower apnea-hypopnea index despite comparable symptom burden. Since the symptoms overlap so closely with the expected menopause picture, the diagnosis requires the question to be asked deliberately instead of being triggered by the presentation.

Vasomotor events cause arousals, and what turns repeated arousals into chronic insomnia is the same set of perpetuating factors that operate in any insomnia: extended time in bed diluting sleep pressure, conditioned arousal to the bedroom, and anticipatory worry about the night ahead. CBT-I targets those maintaining factors instead of the trigger, which is why trials in menopausal women show improvement in sleep outcomes even where hot flash frequency is unchanged, and why some report reduced bother from the flashes themselves. It combines with treatment aimed at the vasomotor symptoms instead of competing with it.

Ready when you are